[go: up one dir, main page]

EP3503875A4 - Water soluble compositions comprising purified cannabinoids - Google Patents

Water soluble compositions comprising purified cannabinoids Download PDF

Info

Publication number
EP3503875A4
EP3503875A4 EP17847412.8A EP17847412A EP3503875A4 EP 3503875 A4 EP3503875 A4 EP 3503875A4 EP 17847412 A EP17847412 A EP 17847412A EP 3503875 A4 EP3503875 A4 EP 3503875A4
Authority
EP
European Patent Office
Prior art keywords
water soluble
soluble compositions
purified cannabinoids
cannabinoids
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17847412.8A
Other languages
German (de)
French (fr)
Other versions
EP3503875A1 (en
Inventor
Kurt Aron LEVY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canopy Growth Corp
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of EP3503875A1 publication Critical patent/EP3503875A1/en
Publication of EP3503875A4 publication Critical patent/EP3503875A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EP17847412.8A 2016-08-29 2017-08-29 Water soluble compositions comprising purified cannabinoids Pending EP3503875A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380954P 2016-08-29 2016-08-29
PCT/US2017/049219 WO2018044953A1 (en) 2016-08-29 2017-08-29 Water soluble compositions comprising purified cannabinoids

Publications (2)

Publication Number Publication Date
EP3503875A1 EP3503875A1 (en) 2019-07-03
EP3503875A4 true EP3503875A4 (en) 2020-06-24

Family

ID=61301487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17847412.8A Pending EP3503875A4 (en) 2016-08-29 2017-08-29 Water soluble compositions comprising purified cannabinoids

Country Status (10)

Country Link
US (6) US10568865B2 (en)
EP (1) EP3503875A4 (en)
CN (1) CN110177543A (en)
AU (1) AU2017319320B2 (en)
BR (1) BR112019003815A2 (en)
CA (1) CA3034004C (en)
CL (1) CL2019000474A1 (en)
CO (1) CO2019002744A2 (en)
MX (1) MX380850B (en)
WO (1) WO2018044953A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034004C (en) 2016-08-29 2021-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
WO2019130201A1 (en) * 2017-12-29 2019-07-04 Buzzelet Development And Technologies Ltd Purified cannabis extracts and methods for production thereof
EP3743055B1 (en) 2018-01-23 2024-03-06 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds
CN112969452A (en) 2018-04-09 2021-06-15 艾乐文特科学公司 Cannabis sativa extract for treating animal pain
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids
WO2020150616A1 (en) * 2019-01-17 2020-07-23 Synthonics, Inc. Solid micellar compositions of cannabinoid acids
US10993928B2 (en) * 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
US10780075B1 (en) 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
MX2022001802A (en) * 2019-08-10 2022-03-11 Locus Ip Co Llc Methods for increasing the bioavailability of otc and pharmaceutical drugs.
JP2022548377A (en) * 2019-09-18 2022-11-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Compositions of cannabinoids for delivery by inhalation
US11186944B1 (en) * 2019-10-23 2021-11-30 Sam Salem And Son, Llc Method of making polyester fabric treated with a CBD powder
CN112915121A (en) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 Cannabinoid nano micelle preparation and preparation method thereof
US20220142969A1 (en) * 2019-12-31 2022-05-12 Soluscience, Llc Water-soluble cannabinoid formulations and methods of their making
CA3078970A1 (en) * 2020-04-16 2021-10-16 National Research Council Of Canada Water soluble formulations containing cannabinoids
CN114748429A (en) * 2020-12-29 2022-07-15 汉义生物科技（北京）有限公司 Water-soluble cannabinoid formulation and method of making same
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
EP4346763A1 (en) * 2021-05-31 2024-04-10 Cannabotech Ltd. Compositions comprising a cannabinoid and uses thereof
AU2023224515A1 (en) * 2022-02-28 2024-09-19 Emyria Cannabinoid dosage form
DE202022102593U1 (en) 2022-05-12 2022-05-30 DÖHLER GmbH Composition with cannabinoids and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US20060257463A1 (en) * 2002-05-31 2006-11-16 University Of Mississippi Transmucosal delivery of cannabinoids
WO2018011808A1 (en) * 2016-07-14 2018-01-18 Icdpharma Ltd Self-emulsifying compositions of cannabinoids

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20030101902A1 (en) 2001-12-04 2003-06-05 Ann Reitnauer Hot melt inks
BRPI0415741B1 (en) 2003-11-07 2013-07-23 tobacco compositions and methods of manufacturing a tobacco composition
GB0329635D0 (en) 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
FR2885619B1 (en) 2005-05-13 2011-02-11 Imaje Sa LIQUID, FOOD, INGERABLE INK COMPOSITION FOR INKJET PRINTING
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
US7923026B2 (en) 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
US20090098192A1 (en) 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
DE102009019322A1 (en) 2009-04-30 2010-11-11 The Health Concept Gmbh Process for the preparation of synthetic cannabinoids
US20110052694A1 (en) 2009-08-31 2011-03-03 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (en) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 Use of plant cannabinoid cannabinol (CBDV) for the treatment of epilepsy
WO2011135591A2 (en) 2010-04-29 2011-11-03 Shasun Pharmaceuticals Limited Novel tablet composition of polyallylamine polymers
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
JP6368242B2 (en) 2011-10-06 2018-08-01 ノバルティス アーゲー Pharmaceutical composition comprising 40-O- (2-hydroxy) ethyl-rapamycin
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
WO2014100231A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
EP4137142A1 (en) 2013-03-14 2023-02-22 Purple Mundo, Inc. Bioactive concentrates and uses thereof
CN105050417B (en) 2013-03-29 2018-05-29 洲际大品牌有限责任公司 Transparent and translucent liquid centre-filled candies, its preparation method, liquid edible composition without sugar and application thereof
US9056049B2 (en) 2013-05-30 2015-06-16 Chin Yuan Huang Micro-particle comprising a protein extract from sweet potato for extending satiety and controlling blood glucose and lipid levels
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
EP3001811B1 (en) 2013-10-29 2016-12-21 Echo Pharmaceuticals B.V. Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
JP2016537412A (en) 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． Terpenes and cannabinoid formulations
WO2015074137A1 (en) 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
US20160022627A2 (en) 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9861611B2 (en) * 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
WO2016109624A1 (en) 2014-12-30 2016-07-07 University Of Houston System Pharmaceutical compositions
US20170266153A1 (en) 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
US20160250270A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
CA3034004C (en) 2016-08-29 2021-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
WO2018142403A1 (en) 2017-02-02 2018-08-09 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
PE20200731A1 (en) 2017-09-28 2020-07-23 Canopy Growth Corp EDIBLE CANNABINOID COMPOSITIONS
CA3104795A1 (en) 2018-06-28 2020-01-02 Canopy Growth Corporation Compositions and methods for agonizing the cb2 receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US20060257463A1 (en) * 2002-05-31 2006-11-16 University Of Mississippi Transmucosal delivery of cannabinoids
WO2018011808A1 (en) * 2016-07-14 2018-01-18 Icdpharma Ltd Self-emulsifying compositions of cannabinoids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018044953A1 *

Also Published As

Publication number Publication date
MX2019002198A (en) 2019-08-16
US20190183853A1 (en) 2019-06-20
MX380850B (en) 2025-03-12
BR112019003815A2 (en) 2019-05-21
US20200121637A1 (en) 2020-04-23
CL2019000474A1 (en) 2019-05-10
US20200253924A1 (en) 2020-08-13
CA3034004C (en) 2021-08-03
US20210308098A1 (en) 2021-10-07
US11510897B2 (en) 2022-11-29
WO2018044953A1 (en) 2018-03-08
US20210308097A1 (en) 2021-10-07
CA3034004A1 (en) 2018-03-08
US10842773B2 (en) 2020-11-24
AU2017319320B2 (en) 2023-08-03
US10722490B2 (en) 2020-07-28
AU2017319320A1 (en) 2019-04-04
US10568865B2 (en) 2020-02-25
EP3503875A1 (en) 2019-07-03
CO2019002744A2 (en) 2019-04-12
CN110177543A (en) 2019-08-27
US20210000791A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
EP3503875A4 (en) Water soluble compositions comprising purified cannabinoids
EP3484468A4 (en) Self-emulsifying compositions of cannabinoids
EP3240555A4 (en) Multi-supplement compositions
EP3346997A4 (en) Bioorthogonal compositions
EP3322441A4 (en) Vaccine compositions
EP3240414A4 (en) Fungicidal compositions
EP3116320A4 (en) Botanical antimicrobial compositions
EP3432870A4 (en) Compositions comprising choline
EP3297455A4 (en) Glycoside compositions
EP3371282A4 (en) Friction-reducing compositions formulated with highly concentrated brine
EP3099381A4 (en) Extended release fragrance compositions
AU2016291708B2 (en) Plinabulin compositions
EP3223628A4 (en) Glycoside compositions
EP3135650A4 (en) Admixture for hydraulic composition
EP3265211A4 (en) Nanolaminated 2-2-1 max-phase compositions
EP3221420A4 (en) Photochromic-electrochromic compositions
EP3221345A4 (en) Metalloprotein compositions
EP3277755A4 (en) Algae-blended compositions without plasticizers
EP3224321A4 (en) Water-based composition
EP3288386A4 (en) Anti-phytopathogenic compositions
EP3373928A4 (en) Novel formulations
EP3310335A4 (en) Long acting liraglutide compositions
EP3157684A4 (en) Illuminated water sprayer
EP3270888A4 (en) Anti-pathogenic compositions
EP3027030A4 (en) Biopesticide compositions comprising water soluble polyols

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200526

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/08 20060101AFI20200518BHEP

Ipc: A61K 31/05 20060101ALI20200518BHEP

Ipc: A61K 31/355 20060101ALI20200518BHEP

Ipc: A61K 47/22 20060101ALI20200518BHEP

Ipc: A61K 31/352 20060101ALI20200518BHEP

Ipc: A61K 9/107 20060101ALI20200518BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009107000

Ipc: A61K0009080000

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 36/185 20060101ALI20250212BHEP

Ipc: A61K 47/22 20060101ALI20250212BHEP

Ipc: A61K 31/355 20060101ALI20250212BHEP

Ipc: A61K 31/352 20060101ALI20250212BHEP

Ipc: A61K 31/192 20060101ALI20250212BHEP

Ipc: A61K 31/05 20060101ALI20250212BHEP

Ipc: A61K 9/107 20060101ALI20250212BHEP

Ipc: A61K 9/08 20060101AFI20250212BHEP